SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 1.7% Stake in Keros Therapeutics
Beneficial Ownership Disclosure
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 1.7% of Keros Therapeutics Inc.'s common stock as of January 31, 2025.
Summary
- FMR LLC and Abigail P. Johnson jointly filed Amendment No. 5 to Schedule 13G concerning their beneficial ownership in KEROS THERAPEUTICS INC.
- As of January 31, 2025, the reporting persons beneficially own an aggregate of 704,472 shares of KEROS THERAPEUTICS INC common stock.
- This beneficial ownership represents 1.7% of the total outstanding class of securities.
- FMR LLC holds sole voting power over 703,293 shares and sole dispositive power over 704,472 shares.
- Abigail P. Johnson holds sole dispositive power over 704,472 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine Schedule 13G filing, which is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the issuer's performance or prospects.
Positives
- A prominent institutional investor, FMR LLC, maintains a beneficial ownership stake in Keros Therapeutics Inc., indicating continued investment interest.
Negatives
- None explicitly stated in this ownership disclosure filing.
Risks
- None explicitly stated in this ownership disclosure filing, as it pertains to beneficial ownership rather than company-specific operational or financial risks.
Future Outlook
This Schedule 13G filing is an ownership disclosure and does not contain forward-looking statements or guidance from Keros Therapeutics Inc. regarding its future outlook.
Management Comments
- The filing includes a certification from FMR LLC and Abigail P. Johnson stating that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of Keros Therapeutics Inc.
Industry Context
This filing is a standard Schedule 13G amendment, reflecting a passive ownership stake by a major institutional investor. It does not provide specific insights into Keros Therapeutics Inc.'s industry trends or competitive landscape, but rather indicates FMR LLC's continued investment in the biotechnology sector.
Comparison to Industry Standards
- This Schedule 13G filing is an ownership disclosure and does not contain information suitable for comparison to industry-specific performance benchmarks or competitor results.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- No litigation or regulatory matters concerning Keros Therapeutics Inc. are disclosed in this filing.
Related Party Transactions
- No related party dealings involving Keros Therapeutics Inc. are disclosed in this filing. The document describes the relationship between FMR LLC and Abigail P. Johnson as part of the reporting entity's structure.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming FMR LLC's continued beneficial ownership of 1.7% of the common stock.
Next Steps
- No specific future actions, events, or milestones for Keros Therapeutics Inc. are mentioned in this ownership disclosure.
Key Dates
| Date | Description |
|---|---|
| January 3, 2023 | Effective date of Power of Attorney for FMR LLC. |
| January 10, 2023 | Date of Schedule 13G filing by FMR LLC (accession number: -23-000003). |
| January 26, 2023 | Effective date of Power of Attorney for Abigail P. Johnson. |
| January 31, 2023 | Date of Schedule 13G filing by FMR LLC (accession number: -23-000038). |
| January 31, 2025 | Date of event which requires filing of this statement. |
| February 6, 2025 | Date of this Schedule 13G filing. |
Keywords
Keros Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.